Piper Jaffray Companies Comments on Vericel Corp’s Q4 2019 Earnings (VCEL)

Vericel Corp (NASDAQ:VCEL) – Investment analysts at Piper Jaffray Companies increased their Q4 2019 earnings per share estimates for Vericel in a report released on Tuesday, November 6th. Piper Jaffray Companies analyst E. Tenthoff now expects that the biotechnology company will earn $0.07 per share for the quarter, up from their previous estimate of $0.06.

VCEL has been the topic of a number of other research reports. BTIG Research restated a “buy” rating and issued a $17.00 target price on shares of Vericel in a report on Tuesday, August 7th. BidaskClub lowered Vericel from a “hold” rating to a “sell” rating in a report on Tuesday, October 23rd. Needham & Company LLC dropped their target price on Vericel from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, August 8th. Finally, LADENBURG THALM/SH SH upgraded Vericel from a “neutral” rating to a “buy” rating in a report on Monday, July 16th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Vericel presently has an average rating of “Buy” and a consensus target price of $16.75.

VCEL stock opened at $16.13 on Wednesday. Vericel has a twelve month low of $3.30 and a twelve month high of $17.26. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.48 and a current ratio of 7.72. The company has a market capitalization of $513.57 million, a PE ratio of -32.27 and a beta of 3.36.

Vericel (NASDAQ:VCEL) last posted its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.09. Vericel had a negative return on equity of 37.86% and a negative net margin of 23.35%. The company had revenue of $22.50 million for the quarter, compared to analyst estimates of $18.14 million. The business’s quarterly revenue was up 57.3% compared to the same quarter last year.

In related news, insider Dominick Colangelo sold 75,000 shares of Vericel stock in a transaction on Thursday, October 4th. The stock was sold at an average price of $15.02, for a total transaction of $1,126,500.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Gerard J. Michel sold 15,000 shares of Vericel stock in a transaction on Monday, September 10th. The stock was sold at an average price of $12.35, for a total value of $185,250.00. Following the sale, the chief financial officer now owns 165,960 shares in the company, valued at $2,049,606. The disclosure for this sale can be found here. Insiders sold 114,000 shares of company stock worth $1,609,770 in the last 90 days. Corporate insiders own 4.70% of the company’s stock.

A number of institutional investors have recently modified their holdings of VCEL. Capital Fund Management S.A. bought a new stake in Vericel during the second quarter worth $104,000. Quantitative Systematic Strategies LLC bought a new stake in shares of Vericel in the second quarter valued at $108,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Vericel in the second quarter valued at $116,000. Commonwealth Equity Services LLC bought a new stake in shares of Vericel in the second quarter valued at $123,000. Finally, Metropolitan Life Insurance Co. NY bought a new stake in shares of Vericel in the second quarter valued at $128,000. Institutional investors and hedge funds own 76.57% of the company’s stock.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.

Further Reading: Why is the ex-dividend date different from the record date?

Earnings History and Estimates for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply